The killing kinetics of meropenem against sixteen clinical isolates of pneumococci (12 penicillin-resistant, three penicillin-intermediate and one penicillin-sensitive) were studied. Meropenem was tested at 1 x , 2 x and 4 x the MIC for each individual isolate. The results showed a good bactericidal activity with rapid killing of pneumococci (killing > 3 logio cfu/mL was obtained for nine strains). This strategy needs clinical assessment and might prove to be a suitable alternative to penicillin and cephalosporins for the treatment of mixed infections involving multiresistant pneumococci.
Introduction
Penicillin-resistant Streptococcus pneumoniae are becoming more common and are often resistant to many antibiotics. Meropenem is a novel dehydropeptidase-I stable carbapenem which shows good activity against penicillin-resistant pneumococci and does not seem to have the epileptogenic potential of imipenem in meningitis, thus could be an alternative for the treatment of meningitis due to strains resistant to penicillins and cephalosporins. Antibiotics which kill bacteria rapidly are recommended for the treatment of severe infections. Time-kill studies are labour intensive and time-consuming, so few studies on antibiotic killing of pneumococci have been published. This study reports the killing kinetics of meropenem against clinical isolates of penicillin-resistant pneumococci.
Methods

Organisms
Sixteen strains of S. pneumoniae were tested (one penicillin-sensitive, three penicillin-intermediate and 12 penicillin-resistant strains). They were isolated from deep pulmonary secretions, blood cultures and cerebrospinal fluid.
Antibiotics
Meropenem (Zeneca, Paris, France) and penicillin G (Specia, Paris, France) were provided as laboratory standard powders.
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Susceptibility testing
MICs were measured by the agar dilution method with a Steer's replicator. Inocula were prepared from a 3 h glucose pneumococcal buffered broth culture (Diagnostics Pasteur, France), grown at 37°C in a shaking bath. Cultures were diluted to an inoculum of lO^cfu/spot applied to Mueller-Hinton agar (Diagnostics Pasteur) supplemented with 5% horse blood and containing dilutions of antibiotics. The MIC was defined as the lowest concentration of each antibiotic that inhibited visible growth.
Killing curves
Killing curves assays were performed with meropenem at a concentration of 1 x , 2 x and 4 x the MIC for each particular isolate. A final inoculum of 10 5 -10 6 cfu/mL, prepared from a pneumococcal broth culture shaken for 3-5 h at 37°C, was then shaken with meropenem at three different concentrations at 37°C, and without meropenem. Viable counts were determined after 0, 3 and 6 h with a spiral inoculator (Interscience, Saint-Nom-La Breteche, France) on Mueller-Hinton agar supplemented with 5% horse blood. Colonies were counted after overnight incubation at 37°C in air containing 10% CO 2 . The lower detection limit was lOcfu/mL. In our experience, and that of others (Yourassowsky et al., 1988) , the low antibiotic concentrations that were used, meant that antibiotic carry-over was unlikely to occur. Killing curve assays of antimicrobial activity were performed at least twice. A bactericidal effect was defined as 99.9% killing (reduction in viable bacteria of ;> 3 logio cfu/mL).
Results and discussion
The results of the MIC determinations are summarized in Table I . These pneumococci were grouped according to previous established criteria for penicillin G MICs (Jacobs et al., 1978) Table II . These data are geometric means of the various experiments (at least three) and are expressed as logio changes in the numbers of surviving bacteria in the antimicrobial tests at 3 and 6 h compared with the antibiotic-free control at 0 h. Meropenem was bactericidal at 2 x MIC after 3 h for two strains including the penicillin-intermediate strain (nos 2, 7) and after 6 h for five more strains (nos 1,4, 5, 13, 15). Killing > 3 logio after 6 h was seen at 4 x MIC for nine strains including one penicillin-susceptible (no. 1), two penicillin-intermediate (nos 2, 4) and six penicillin-resistant strains (nos 5, 7, 8, 9, 13, 15) . At 3 h the geometric mean reductions for x 1, x2 and x4 MIC are respectively 1.22, 1.86, 2.31 and at 6 h 2.01, 2.80, 3.28. So there is a significant increase in the bactericidal activity within increasing concentration.
Penicillin-resistant pneumococci are becoming world-wide and they often show resistance to multiple antibiotics including third generation cephalosporins. The choice of antibiotics is becoming more limited for the treatment of severe infections including meningitis caused by such strains.
Penicillin-resistant pneumococci are more resistant than penicillin susceptible strains to all currently available /J-lactam agents; among these imipenem is the most active in vitro (Tweardy, Jacobs & Speck, 1983) . Time kill studies indicate a good bactericidal activity of imipenem with rapid killing of pneumococci (Barakett et al., 1994) . Meropenem is a novel dehydropeptidase-I stable carbapenem which shows good activity against penicillin-resistant pneumococci (Spangler, Jacobs & Appelbaum, 1994) and does not seem to have the epileptogenic potential of imipenem in meningitis. In our study, all strains were susceptible to meropenem with MICs < 0.5 mg/L. Low imipenem MICs for all groups of pneumococci have been described before (Linares et al., 1992) as well as comparably low MICs of meropenem for such organisms (Spangler et al., 1994) even though meropenem could be considered slightly less active than imipenem against pneumococci. The achievable CSF levels of meropenem following 40 mg per kg dose administrated to patients with bacterial meningitis (Dagan et al., 1994) exceed the maximum concentration used in our experiments which is 2 /ig/mL (4 x MIC).
Rapid killing of bacteria must be obtained for effective therapy particularly for bacterial meningitis. There are very few reports of time-kill experiments with S. pneumoniae. Edwards et al. (1994) reported the good bactericidal activity of meropenem on two strains of 5. pneumoniae. For either strain 4 x MIC of meropenem (0.04 mg/L for the penicillin susceptible and 1 mg/L for the penicillin resistant strain) achieved a 3 log reduction in 4 h. The results of our time-kill experiments performed on 16 strains (12 penicillin resistant, three penicillin intermediate and one penicillin sensitive) showed a 3 log reduction at 4 x MIC for nine strains at 6 h. These results are encouraging.
Furthermore meropenem was found bactericidal in two models of experimental meningitis. Nairn el al. (1995) evaluated meropenem and other antibiotics in a model of bacterial meningitis in the guinea-pig caused by three strains of S. pneumoniae. Against penicillin resistant pneumococci meropenem was significantly more effective than ceftriaxone. Friedland et al. (1993) evaluated meropenem in a model of rabbit Table I . MICs of penicillin and meropenem for penicillin-resistant, -intermediate and -susceptible pneumococci meningitis induced by intracisternal inoculation of two penicillin and ceftriaxone resistant pneumococcal strains. Meropenem was less bactericidal than cefpirome, vancomycin and clinofloxacin. The lower bactericidal rate observed with meropenem may be due to its rapid metabolism in rabbits.
To date two randomised multicentre clinical trials (Klugman et al., 1995 , Schmutzhard et al., 1995 have found meropenem to be highly effective in eradicating S. pneumoniae from both adults and children with meningitis and to be at least as effective as the cephalosporins cefotaxime and ceftriaxone.
Time-kill studies are labour intensive and time-consuming. Usually very few bacterial strains are studied and so generalizations may not be warranted. In this respect our in-vitro results suggest that meropenem performs better than imipenem against 5. pneumoniae (Barakett et al., 1994) and had a comparable efficacy and tolerability to imipenem/cilastatin and various other treatment regimens. In addition meropenem does not appear to increase the risk of seizures in patients with preexisting central nervous system disorders, enabling it to be used in patients with meningitis.
Meropenem is likely to be of greatest value in the treatment of severe infections and those caused by multiply resistant bacteria including penicillin and cephalosporin resistant pneumococci. Although further clinical experience (including prospective clinical trials) is necessary to ultimately define its place in therapy.
